MedTrace Logo

Vomiting Prevention in Children With Cancer

NCT06886451 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1332

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients.

The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will:

Primary

1\. Reduce the proportion with any vomiting within the 96-hour window

Secondary

1. Reduce the number of vomiting episodes
2. Increase the proportion receiving care pathway-consistent care
3. Impact on number of administrations and costs of antiemetic medications

Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.

Conditions

  • Chemotherapy Induced Nausea and Vomiting
  • Quality of Life (QOL)
  • Pediatric Cancer

Interventions

OTHER

ML-based intervention

For each patient, a ML model will predict the risk of vomiting within the next 96 hours. Patients will then receive care pathway-consistent interventions based on the ML model predictions.

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Lillian Sung, MD, PhD · The Hospital for Sick Children

  • Lee Dupuis, RPh, PhD · The Hospital for Sick Children

  • Priya Patel, PharmD · The Hospital for Sick Children

  • Adam Yan, MD, MBI · The Hospital for Sick Children

  • Lawrence Guo, PhD · The Hospital for Sick Children

  • Santiago Arciniegas, MSc · The Hospital for Sick Children

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2027-03-18
Completion
2027-03-18

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06886451 on ClinicalTrials.gov